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Abstract
A coordinated, multidisciplinary approach to care is essential for optimum management of the 
primary manifestations and secondary complications of Duchenne muscular dystrophy (DMD). 
Contemporary care has been shaped by the availability of more sensitive diagnostic techniques and 
the earlier use of therapeutic interventions, which have the potential to improve patients’ duration 
and quality of life. In part 2 of this update of the DMD care considerations, we present the latest 
recommendations for respiratory, cardiac, bone health and osteoporosis, and orthopaedic and 
surgical management for boys and men with DMD. Additionally, we provide guidance on cardiac 
management for female carriers of a disease-causing mutation. The new care considerations 
acknowledge the effects of long-term glucocorticoid use on the natural history of DMD, and the 
need for care guidance across the lifespan as patients live longer. The management of DMD looks 
set to change substantially as new genetic and molecular therapies become available.
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Introduction
The 2010 care considerations for Duchenne muscular dystrophy (DMD)1,2 advocated a 
multidisciplinary approach to the management of this severe, progressive neuromuscular 
disease. This three-part update was necessitated by a number of themes that characterise 
contemporary DMD care: the increasing complexity of subspecialty care and the need for a 
multidisciplinary clinical team; the use of more sensitive diagnostic techniques and earlier 
therapeutic interventions; the expectation of prolonged survival, prompting the need for care 
guidance across the lifespan; and the recognition that the natural history of DMD has been 
altered by the long-term use of glucocorticoids.3 The new care considerations have also been 
shaped by the expectation that emerging genetic and molecular therapies will substantially 
change the nature of DMD management in the near future.
In 2014, the DMD Care Considerations Working Group steering committee, comprising 
experts from a wide range of disciplines, identified 11 topics to be included in this update. 
Part 2 contains the latest care considerations for respiratory, cardiac, bone health and 
osteoporosis, and orthopaedic and surgical management. Large-scale, randomised controlled 
trials (RCTs) are rare in this field, so guidance was developed using a method that queries a 
group of experts on the appropriateness and necessity of specific assessments and 
interventions, using clinical scenarios. This methodology was designed to produce an 
essential toolkit for DMD care; only assessments and interventions that have been deemed 
both appropriate and necessary are recommended. A complete description of the methods is 
provided in part 1 and the appendix.
Figure 1 in part 1 of this Review provides a brief overview of assessments and interventions 
across all topics, organised by stage of disease. It is intended to serve as a pocket guide to 
overall disease management.
Respiratory management
Respiratory complications are a major cause of morbidity and mortality in people with 
DMD. Complications include respiratory muscle fatigue, mucus plugging, atelectasis, 
pneumonia, and respiratory failure. If left untreated, patients are at risk of severe dyspnoea, 
lengthy hospital admissions due to atelectasis or pneumonia, and death due to respiratory 
arrest or respiratory-induced cardiac arrhythmias.4-6
An anticipatory approach to management includes monitoring of respiratory muscle function 
and the timely use of lung volume recruitment, assisted coughing, nocturnally assisted 
ventilation, and subsequent daytime ventilation. These core therapies can decrease 
respiratory complications, improve quality of life, and prolong survival.4,7-10 Patients should 
typically be using most or all of these core therapies by the age of 18–21 years, before their 
transition from paediatric to adult respiratory care providers.
Implementation of respiratory care considerations and guidelines1,2,11-15 requires a 
multidisciplinary team— including physicians, respiratory therapists (or physical therapists 
in some health-care systems), and home caregivers—to perform pulmonary function testing 
and sleep studies and to initiate and manage lung volume recruitment,16 manual and 
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mechanically assisted coughing,5,17 non-invasive ventilation, and invasive ventilation via 
tracheostomy. Decisions for optimum respiratory management need to be made with 
awareness of the patient’s other body systems, especially the cardiac system.10,18
In this update, we endorse higher pulmonary function thresholds (ie, milder levels of 
respiratory impairment) for initiation of assisted coughing and assisted ventilation than were 
recommended in the 2010 care considerations. The new criteria are intended to result in 
more anticipatory use of these interventions, with the possibility that therapy will be initiated 
in slightly younger patients.
Ambulatory stage
Figure 1 shows respiratory diagnostic tests and therapies for individuals with DMD, by stage 
of disease. Spirometry should be initiated when the patient is 5–6 years of age. Serial 
monitoring of pulmonary function is critical for respiratory management. Typically, forced 
vital capacity (FVC) rises with growth, until an individual becomes non-ambulatory. FVC 
reaches a peak, followed by a plateau, and then deteriorates over time.19-21 Deteriorating 
FVC can occur in the absence of dyspnoea and remain unrecognised unless pulmonary 
function is measured regularly. In a large cohort study in boys who had not been treated with 
corticosteroids, the age at loss of ambulation was predictive of the age at which peak FVC 
was realised, the absolute peak FVC, and the rate of subsequent decline.19 For example, 
earlier loss of ambulation was associated with an earlier and lower peak FVC as well as a 
more rapid decline in FVC than was later loss of ambulation. However, because the rate of 
change in FVC over time can vary greatly among individuals, serial measurement of FVC is 
necessary to characterise each individual’s respiratory phenotype or trajectory.
Sleep studies with capnography might be necessary during the ambulatory stage, especially 
for individuals with weight gain due to glucocorticoid therapy and for individuals with 
symptoms of sleep-disordered breathing. Sleep studies can also be used as an alternative 
method to monitor respiratory status among individuals who cannot cooperate with 
pulmonary function testing.
Individuals with DMD should receive yearly immunisation with the inactivated influenza 
vaccine (ie, the injectable vaccine, not the live, attenuated nasal vaccine) and pneumococcal 
vaccines (including PCV13 and PPSV23), according to guidelines available from the US 
Centers for Disease Control and Prevention,22 other public health entities such as the 
Immunization Action Coalition,23 and Parent Project Muscular Dystrophy.24
Patients and their caregivers should be educated about respiratory complications during the 
ambulatory stage of DMD to prepare them for future medical complications and therapies.
Early non-ambulatory stage
The need for respiratory interventions occurs mainly after the loss of ambulation (figure 1). 
Seated FVC (expressed both as an absolute value and as a percentage predicted on the basis 
of arm span or ulnar length), maximum inspiratory and expiratory pressures, peak cough 
flow, and blood oxygen saturation by pulse oximetry (SpO2) should be measured at least 
every 6 months in all non-ambulatory individuals. Additionally, end-tidal or transcutaneous 
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partial pressure of carbon dioxide in the blood (petCO2 or ptcCO2, respectively) should be 
measured every 6 months or any time SpO2 is 95% or lower on room air, when the necessary 
equipment is available.
As their vital capacity decreases, patients with DMD develop stiff, non-compliant chest 
walls and lung volume restriction. To preserve lung compliance, lung volume recruitment is 
indicated when FVC is 60% predicted or less, achieved with a self-inflating manual 
ventilation bag or mechanical insufflation– exsufflation device to provide deep lung inflation 
once or twice daily.25–27
During the early non-ambulatory stage, some individuals with DMD need surgery for 
progressive scoliosis.28 Previously published guidelines address respiratory management of 
patients undergoing surgery, including indications for preoperative training in the use of 
assisted cough devices and non-invasive ventilators.13 For patients who are cognitively 
impaired and unable to reliably perform pulmonary function testing, preoperative 
polysomnography might be helpful.
Late non-ambulatory stage
As they progress through the non-ambulatory stage, individuals with DMD develop weak 
cough efforts, placing them at risk of atelectasis, pneumonia, ventilation–perfusion 
mismatch, and progression to respiratory failure, especially during respiratory tract 
infections. Treatment consists of manual and mechanically assisted coughing, which are 
indicated when FVC is less than 50% predicted, when peak cough flow is less than 270 L/
min, or when maximum expiratory pressure is less than 60 cm H2O (figure 1).29–31
We advise having a home pulse oximeter for individuals treated with assisted coughing 
during respiratory infections. When SpO2 is less than 95% on room air, the frequency of 
assisted coughing should be increased to prevent and treat mucus plugging, atelectasis, and 
pneumonia. We also recommend initiation of antibiotic therapy during acute respiratory 
illnesses when individuals have three of the following five signs of pneumonia: fever, 
elevated white blood count or C-reactive protein concentration, sputum production, a 
pulmonary infiltrate on chest radiograph, or hypoxaemia or respiratory distress.
In the late non-ambulatory stage, individuals with DMD need assisted ventilation to prolong 
survival.32 Ventilation devices should incorporate a back-up rate of breathing to avoid 
apnoea. Indications for nocturnally assisted ventilation include signs or symptoms of 
hypoventilation or sleep-disordered breathing, irrespective of the level of pulmonary 
function; relevant symptoms include fatigue, dyspnoea, morning or continuous headaches, 
frequent nocturnal awakenings or difficult arousal, hypersomnolence, difficulty 
concentrating, awakenings with dyspnoea and tachycardia, and frequent nightmares. 
However, some individuals remain asymptomatic despite the presence of hypoventilation.33 
Thus, nocturnally assisted ventilation should be initiated when a patient’s FVC is less than 
50% predicted, or when the absolute value of maximum inspiratory pressure is less than 60 
cm H2O. It should also be initiated when the individual is awake and, because of daytime 
hypoventilation, any of the following is true: petCO2 or ptcCO2 is more than 45 mm Hg; 
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arterial, venous, or capillary blood pCO2 is more than 45 mm Hg; or baseline SpO2 is less 
than 95% on room air (figure 1).33–38
Nocturnal ventilation is also indicated for individuals with abnormal sleep studies, including 
overnight oximetry, combination oximetry–capnography, and polysomnography with 
capnography. Non-ambulatory individuals with symptoms of sleep-disordered breathing 
should have sleep studies as often as annually, if possible. Sleep study results that indicate 
the need for assisted ventilation include petCO2 or ptcCO2 of more than 50 mm Hg for at 
least 2% of sleep time, a sleep-related increase in petCO2 or ptcCO2 of 10 mm Hg above the 
awake baseline for at least 2% of sleep time, an SpO2 of 88% or less for at least 2% of sleep 
time or for at least 5 min continuously, or an apnoea–hypopnoea index of five events per h or 
more.37,39 Because patients with DMD inevitably need assisted ventilation to treat 
hypoventilation, nocturnal non-invasively assisted ventilation (rather than continuous 
positive airway pressure at a constant level) is first-line therapy for individuals with DMD 
with obstructive sleep apnoea.
Non-invasive ventilation can also be used during and after procedures involving anaesthesia 
or sedation and, in conjunction with assisted coughing, to extubate individuals who are 
mechanically ventilated for respiratory infections.40 In DMD, hypoxaemia is usually due to 
hypoventilation, atelectasis, or pneumonia. Therefore, supplemental oxygen therapy should 
not be used alone. In conjunction with assisted ventilation and assisted coughing, oxygen 
therapy can be safe, especially when blood CO2 levels are monitored.
With declining pulmonary function, patients develop symptoms of hypoventilation such as 
dyspnoea, fatigue, and difficulty concentrating, despite their use of assisted ventilation 
during sleep; those with very low FVCs (<680 mL in one study41) are at particular risk. 
Thus, patients often self-extend their use of assisted ventilation into the daytime, ultimately 
up to 24 h/day. The indications for daytime-assisted ventilation are listed in figure 1. Options 
for continuous non-invasive ventilation include mouthpiece or so-called sip ventilation with 
a portable volume ventilator during the day, changing to nasal ventilation with a bi-level 
pressure device overnight. Alternatively, 24 h/day nasal ventilation with a bi-level pressure 
device can be effective and well tolerated.7,9,42 These devices should have an internal battery 
for safety and portability.
Whether individuals with DMD should be ventilated via tracheostomy or non-invasively is a 
controversial question. Some centres use time on the ventilator (eg, 16 h/day or more) as an 
indication for tracheostomy.43–45 However, clinical experience supports the use of non-
invasively assisted ventilation for up to 24 h/day.7,42,46 We strongly endorse the use of non-
invasive ventilation in most clinical situations. Our indications for tracheostomy are listed in 
figure 1, and include patient preference, inability to use non-invasive ventilation, three failed 
extubation attempts during a critical illness despite optimum use of non-invasive ventilation 
and mechanically assisted coughing, or failure of noninvasive methods of cough assistance 
to prevent aspiration of secretions into the lungs due to weak bulbar muscles. Overall, the 
decision is highly dependent on each individual’s preference and clinical course, the skills 
and usual practices of the individual’s clinicians, the local standard of care, and the 
availability of home resources, such as overnight nursing.47 The use of non-invasive 
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respiratory aids is especially challenging when individuals with very advanced DMD have 
acute respiratory illnesses and when they have chronic difficulty swallowing their saliva.
Continuous ventilation provides life support, so a back-up ventilator and a manual 
resuscitator should be available in case the primary ventilator malfunctions. Batteries or a 
generator should be available for use during a power outage. The ventilation device and 
battery should attach to the individual’s wheelchair for mobility and quality of life. When 
practical, the presence of a night nurse can greatly decrease the risk of potentially 
catastrophic medical events, such as mucus plugging of the trachea.
Cardiac management
Cardiovascular complications are a leading cause of disease-related morbidity and mortality 
among individuals with DMD.48 Dystrophin deficiency in the heart manifests as a 
cardiomyopathy. As the disease progresses, the myocardium fails to meet physiological 
demands and clinical heart failure develops. The failing myocardium is also at risk of life-
threatening rhythm abnormalities.49
Historically, individuals with DMD have not been referred to a cardiac specialist until late in 
the disease, contributing to poor clinical outcomes. Furthermore, cardiac management has 
been challenging because the New York Heart Association classification of heart failure50 
relies on reduced exercise tolerance, a feature that in DMD arises from skeletal muscle and 
cardiac disease combined. The signs and symptoms of heart failure in the non-ambulatory 
individual are frequently subtle and overlooked. A proactive strategy of early diagnosis and 
treatment is essential to maximise duration and quality of life. Involvement of a cardiologist 
who is integrated into a multidisciplinary care team is recommended, given the complex 
decision making involved in managing DMD cardiomyopathy. Ideally, the cardiologist 
should have clinical expertise in diagnosing and treating heart failure and the 
cardiomyopathy associated with neuromuscular disease, and have readily available access to 
state-of-the-art expertise in noninvasive imaging. A National Heart, Lung, and Blood 
Institute (NHLBI) expert working group was convened and recently published updated 
comprehensive DMD cardiac care considerations, including important areas for future 
research.51 The specific core care considerations are detailed below and summarised in 
figure 2.
Ambulatory stage and early non-ambulatory stage
The baseline cardiac assessment includes past and present cardiac medical history, family 
history, and a physical examination. Electrocardiogram and non-invasive imaging are 
advised to establish baseline cardiac function and to screen for underlying anatomical 
abnormalities that could affect long-term cardiovascular health. Cardiovascular MRI (CMR) 
is the non-invasive imaging modality of choice; however, young individuals might not be 
able to cooperate for the procedure. Thus, echocardiography is recommended until at least 
age 6-7 years, when CMR can typically be done without anaesthesia. Until the age of 10 
years, individuals should have an annual cardiac assessment, including electrocardiogram 
and non-invasive imaging. After the age of 10 years, asymptomatic individuals should have a 
cardiac assessment at least annually because of the increased risk of left ventricular 
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dysfunction. With the onset of heart failure symptoms or when abnormalities are first seen 
on cardiac imaging—eg, myocardial fibrosis, left ventricular enlargement, or left ventricular 
dysfunction—the frequency of assessment should increase at the discretion of the 
cardiologist. An electrocardiogram and non-invasive cardiac imaging should be done before 
major surgical procedures, such as scoliosis correction. DMD is associated with a particular 
set of anaesthesia risks, and the anaesthetist should be made aware of the patient’s cardiac 
history.52
Traditionally, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor 
blockers (ARBs) were used as first-line therapy for the treatment of heart disease associated 
with DMD. Opinion differs on the use of ACE inhibitors in very young (<10 years) 
asymptomatic individuals without evidence of abnormality on CMR or echocardiogram. 
After discussing potential benefits and risks with the family, the cardiologist could initiate 
therapy in this group of individuals. Some evidence suggests that initiation of ACE 
inhibitors in asymptomatic boys with normal left ventricular systolic function as they 
approach 10 years of age can improve long-term cardiac outcomes, and the 2014 NHLBI 
working group recommended use of ACE inhibitors or ARBs by the age of 10 years in boys 
with DMD.51 Dosing and ACE inhibitor selection are left to the discretion of the 
cardiologist.53
Irrespective of age, pharmacological therapy should be initiated with the onset of heart 
failure symptoms or when abnormalities such as depressed left ventricular ejection fraction, 
abnormal chamber dimensions, or the presence of myocardial fibrosis are noted on imaging 
studies (CMR or echocardiogram). Given the absence of dystrophin-specific targeted cardiac 
therapies, traditional treatment strategies for heart failure should be used. β-adrenergic 
blockade is typically started with evidence of ventricular dysfunction. In a prospective, 
randomised double-blind placebo-controlled trial in patients aged 7-25 years with DMD, the 
mineralocorticoid receptor antagonist eplerenone attenuated the decline in cardiac function, 
as measured by circumferential strain.54 This benefit was supported by findings from a 2 
year, open-label extension trial.55 However, although eplerenone might prove to be a useful 
adjunctive therapy to other heart failure medications, further investigations are needed to 
establish effectiveness.54,55
Late non-ambulatory stage
Progressive myocardial fibrosis leads to ventricular dysfunction. More frequent cardiac 
monitoring, as determined by the patient’s cardiologist, is advised in the late, non-
ambulatory stage to reduce disease-related morbidity and mortality. The cardiologist should 
work closely with the multidisciplinary care team to ensure that respiratory care has been 
optimised, because abnormal pulmonary mechanics affect cardiac function.56,57 Specifically, 
there is evidence that noninvasive nocturnal ventilation increases long-term survival.8 The 
NHLBI working group suggested that early initiation of nocturnal ventilation be considered 
because of potential long-term benefit.51
Symptomatic heart failure can be particularly difficult to diagnose in non-ambulatory 
patients with DMD. Clinical manifestations of heart failure—fatigue, weight loss, vomiting, 
abdominal pain, sleep disturbance, and inability to tolerate daily activities—are often 
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unrecognised until late in the disease because of musculoskeletal limitations. The 
cardiologist should maximise medical therapy for heart failure. Consideration should also be 
given to thromboembolism prevention in individuals with severe left ventricular dysfunction. 
Various antithrombotic drugs are available, and should be initiated after discussion with the 
cardiologist.
People with DMD are at risk of rhythm abnormalities— including atrial fibrillation or 
flutter, ventricular tachycardia, and ventricular fibrillation—that can be treated with standard 
antiarrhythmic medications or device management, when indicated. Surveillance should 
include periodic Holter monitoring. In most circumstances, 24 h Holter monitoring will be 
sufficient. Event monitors could also be indicated when individuals complain of episodic, 
non-sustained rhythm disturbances. The optimum frequency of monitoring has not been 
established and should be directed by the cardiologist, depending on the patient’s clinical 
course. It is reasonable to initiate annual Holter monitor screening with the onset of 
abnormal left ventricular function or development of myocardial fibrosis. The benefit of 
implantable cardioverter defibrillators as primary prevention for ventricular tachycardia or 
ventricular fibrillation is unknown. These devices can be used for secondary prevention in 
patients who have had ventricular tachycardia or ventricular fibrillation. At present, 
placement for primary arrhythmia prevention is on the basis of established adult heart failure 
guidelines. Among adults with heart failure, placement of implantable cardioverter 
defibrillators is advised for individuals with an ejection fraction of less than 35%.58 Clearly, 
patients with DMD have unique issues (eg, chest wall deformities and sedation risk), which 
might affect this recommendation.
In individuals in whom maximal medical management has failed, the use of mechanical 
circulatory support is a therapeutic consideration, as illustrated by relevant case reports. A 
left ventricular assist device could be used as a destination therapy—ie, in individuals for 
whom a heart transplant is not considered appropriate.59-61 The decision to proceed with a 
ventricular assist device is complex and involves a deep understanding of all the inherent 
risks and potential benefits. Risks include, but are not limited to, thromboembolism, 
bleeding, infection, device malfunction, and right heart failure. In an ideal situation, the 
device has the potential to improve duration and quality of life. Cardiac transplantation is 
also a theoretical option, but given the small number of available donors, it needs to be 
considered on a case-by-case basis.
Female carriers
In this update, we acknowledge that female carriers of a disease-causing mutation are at risk 
of not only skeletal muscle disease, but also cardiomyopathy.62 The natural history and 
incidence of cardiomyopathy in girls and women is not well characterised, but in a 2016 
study,63 47% of carriers had at least one positive finding on CMR. We recommend a 
baseline cardiac assessment in early adulthood that includes an electrocardiogram and non-
invasive imaging, preferably CMR, when available. Ongoing surveillance will be required, 
on the basis of guidance for individuals with cardiomyopathy.64 The optimum frequency has 
not been established in the DMD carrier population, but our current guidance is for 
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assessment every 3–5 years, on the basis of screening recommendations for other genetic 
cardiomyopathies.65
Bone health and osteoporosis management
Boys with glucocorticoid-treated DMD frequently develop osteoporosis, which manifests as 
low-trauma vertebral or long-bone fractures.66 This outcome is not surprising given the 
potent osteotoxicity of glucocorticoid therapy combined with progressive myopathy, both of 
which are key risk factors for reduced bone strength. 20–60% of boys with DMD have low-
trauma extremity fractures (usually the distal femur, tibia, or fibula), while up to 30% 
develop symptomatic vertebral fractures.66–68 Vertebral fractures are frequently 
asymptomatic when identified in children with glucocorticoid-treated illnesses through a 
monitoring programme that includes a lateral spine radiograph,69-73 so the true prevalence is 
probably higher than existing reports suggest. Left untreated, vertebral fractures can lead to 
chronic back pain and spine deformity, while leg fractures can cause premature, permanent 
loss of ambulation.66 Death due to fat embolism syndrome after long-bone fractures has also 
been reported in boys with DMD.74,75
The notion that some glucocorticoid agents and dosing regimens are bone-sparing compared 
with others has arisen from studies of deflazacort versus prednisone or meprednisone (also 
known as methylprednisone) in children after renal transplant and in those with chronic 
juvenile arthritis.76-78 The steroid dose equivalences used in these studies were variable, 
making comparisons difficult; however, disease outcomes were favourable in the 
deflazacort-treated children, with associated improvements in bone density outcomes, linear 
growth, weight–height ratios, and lean body mass. By contrast, recent publications cast 
doubt on the bone-sparing properties of deflazacort, showing that bone fragility (including 
vertebral fractures) is frequent in deflazacort-treated boys with DMD, probably related 
partly to the large doses that are used in this condition.73,79 Comparative studies of different 
steroid regimens in DMD are underway, assessing the effect on final adult height, body 
composition, and fractures.80
Despite the high prevalence of fractures, no published studies of DMD or any osteoporotic 
condition of childhood have assessed the safety and efficacy of medical therapy in 
preventing the first-ever fracture. Therefore, the current standard is to identify and treat early 
indications of bone fragility (eg, vertebral fractures) in individuals with chronic illnesses 
who have little possibility of recovery. This secondary prevention approach has the goal of 
mitigating osteoporosis progression and promoting recovery among patients presenting with 
early, rather than late, indications of osteoporosis and in those with little potential for 
medication-unassisted recovery because of persistent risk factors.
We present care considerations for monitoring that will enable timely diagnosis and 
treatment of osteoporosis in boys and men with DMD (figure 3). We also review specific 
diagnostic criteria for osteoporosis, along with care considerations for prescription of 
osteoporosis therapy, including agents, dose, and duration of therapy. Comprehensive 
reviews of all issues relating to management of osteoporosis therapy (including 
contraindications and monitoring of safety and efficacy) have been published elsewhere.81,82
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Bone health monitoring and diagnosis of osteoporosis
An important development that distinguishes the current guidance from the 2010 care 
considerations is that bone health monitoring and diagnosis in children no longer focus on 
bone mineral density (BMD); rather, BMD serves as an adjuvant in an approach that focuses 
on identification of the earliest signs of bone fragility. Several observations in children with 
chronic, glucocorticoid-treated illnesses have fuelled this change. First, vertebral fractures—
defined according to the Genant method83 as mild (grade 1), moderate (grade 2), or severe 
(grade 3)—are now understood to be a frequent manifestation of osteoporosis in children 
with chronic illness, including those with glucocorticoid-treated DMD.73,84 As noted, some 
individuals with vertebral fractures are relatively asymptomatic, even in more advanced 
stages of collapse.71 Therefore, to detect vertebral fractures, spine imaging should not be 
prompted solely by back pain or deformity; rather, people with known risk factors for 
vertebral fractures, including motor disorders85 or glucocorticoid therapy,72,84 should 
receive regular spine imaging. The fact that vertebral fractures at any time point in a 
patient’s clinical course are predictive of future spine fractures even when the initial 
vertebral fractures are mild or asymptomatic71—a phenomenon known as the vertebral 
fracture cascade86— underscores the need for early identification.
Vertebral fractures can occur in children who have BMD Z scores higher than −2 SD, an 
observation that invalidates the use of a BMD Z score threshold to define osteoporosis in 
children with low-trauma vertebral fractures.87 This observation prompted the International 
Society for Clinical Densitometry to revise the definition of osteoporosis in a child with a 
low-trauma vertebral fracture so that cutoff criteria based on BMD Z scores are no longer 
required to make the diagnosis of osteoporosis.88 Similarly, 15% of children with 
neuromuscular disorders and extremity fractures will have BMD Z scores for the distal 
femur higher than −2 SD,89 which again challenges the use of a BMD Z score threshold to 
define osteoporosis in a child with extremity fractures. Finally, findings from a recent 
study87 showed that spine BMD Z scores can vary by as much as 2 SD depending on the 
normative database that is used to generate the Z scores. In view of these findings, the 
diagnosis of osteoporosis in at-risk children now rests on the presence of evident bone 
fragility, often manifesting as vertebral fractures, and a BMD Z score above −2 SD does not 
preclude the diagnosis of osteoporosis.88 Although BMD Z scores are no longer at the 
forefront of diagnosis, they remain useful to determine the overall trajectory of bone health 
in an individual child and thereby guide frequency of lateral spine radiographs during the 
monitoring phase.
The 2010 care considerations recommended a spine radiograph for vertebral fracture 
detection in patients with a history of back pain or spine deformity on physical examination. 
In the current care considerations, a baseline spine radiograph for vertebral fracture 
detection is recommended in all patients, with intermittent follow-up radiographs to assess 
changes in spine morphology in the face of persistent (ie, glucocorticoid therapy) or 
permanent (ie, myopathy) risk factors. Given the need for serial spine radiographs, 
assessment by dual-energy x-ray absorptiometry is an emerging method for at-risk 
populations, and a validation study in children has shown that this technique compares 
favourably with detection of Genant-defined vertebral fractures on spine radiographs.90 
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Overall, spine radiographs should be prioritised over BMD in view of the need to detect the 
earliest signs of bone fragility.
Treatment of osteoporosis
Indications for treatment with intravenous bisphosphonate—the presence of low-trauma 
vertebral fractures or long-bone fractures—generally remain unchanged, but with notable 
differences in the timing of treatment initiation. Previously, only back pain or spine 
deformity prompted a radiograph to identify vertebral fractures necessitating bisphosphonate 
therapy. The current call for routine spine radiographs for all patients with DMD will lead to 
diagnosis of symptomatic vertebral fractures (mild, moderate, and severe) and asymptomatic 
moderate and severe vertebral fractures, all of which should prompt referral to an 
osteoporosis expert for treatment. Because even mild and asymptomatic vertebral fractures 
are predictive of future fractures in both children71 and adults,91 treatment of asymptomatic 
moderate (Genant grade 2) and severe (Genant grade 3) vertebral fractures is now 
recommended. Treatment with intravenous bisphosphonate therapy had a protective effect 
on spine BMD and vertebral morphology in controlled trials of osteogenesis imperfecta92-94 
and in uncontrolled studies of osteogenesis imperfecta95 and DM D.84,96 Additional support 
for treatment of asymptomatic but nevertheless advanced (ie, moderate and severe) vertebral 
fractures stems from the fact that no cases of spontaneous (ie, medication unassisted) 
reshaping of previously fractured vertebral bodies have been reported in boys with DMD;73 
however, reshaping has been observed after intravenous bisphosphonate therapy in this 
population.84 For children with glucocorticoid-treated diseases, such as DMD, including 
those with minimally symptomatic or asymptomatic mild (grade 1) vertebral fractures, 
controlled trials are underway to investigate the efficacy of antiresorptive therapy 
(ClinicalTrials.gov identifiers NCT00799266 and NCT02632916); for now, mild 
asymptomatic fractures should be closely monitored for symptomatology or progressive 
height loss that would prompt treatment.
The updated guidance represents a fundamental change in the goals of therapy. The aim is to 
identify and treat the earliest signs of bone fragility to better preserve the heights of the 
vertebral bodies.84 We endorse the use of intravenous (and not oral) bisphosphonates as first-
line therapy for the treatment of osteoporosis in patients with DMD,81,82 on the basis of an 
extrapolation from results of controlled trials in osteogenesis imperfecta. Such studies have 
shown increased vertebral heights in growing patients with osteogenesis imperfecta treated 
with intravenous bisphosphonate therapy.92-94 By contrast, no controlled studies of oral 
bisphosphonates in osteogenesis imperfecta have shown an effect on vertebral height.97-99 
These data are particularly relevant to patients with glucocorticoid-treated DMD, who have a 
high frequency of vertebral fractures.73 Recent reviews on the management of children with 
fractures due to osteoporosis concur with the view that intravenous rather than oral 
bisphosphonates should be used as first-line therapy.81,82 Because bisphosphonates remain 
off label for children in most countries and they require judicious prescription, patients with 
a low-trauma fracture should be referred to an expert in osteoporosis management to ensure 
proper bisphosphonate dosing, dose titration on longer-term therapy, timing of treatment 
cessation, and monitoring of treatment safety and efficacy.
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Orthopaedic and surgical management
The overall aim of musculoskeletal care is to maintain motor function for as long as 
possible, minimise joint contractures, maintain a straight spine, and promote bone health. 
The assessment and treatment of musculoskeletal complications should involve an 
interdisciplinary team that might include a physical and occupational therapist, rehabilitation 
physician, neurologist, orthopaedic surgeon, and social worker. When a surgical intervention 
is recommended, it is crucial to involve the respiratory physician and cardiologist.
Figure 4 outlines the care considerations for orthopaedic and surgical care related to 
contracture, spine, and fracture management. Figure 5 provides general guidance for patients 
and families about fracture prevention. In the absence of RCTs comparing different 
therapeutic and surgical approaches, this guidance is based on the expert consensus of 
orthopaedic and rehabilitation specialists, using the methods described in part 1. Care 
considerations on stretching, orthoses, and adaptive equipment for contracture management 
are provided in the rehabilitation management section of part 1.
Ambulatory stage
Children in the ambulatory stage might benefit most from surgery, but it is recommended 
less frequently than in the past. Although the 2010 care considerations included 
recommendations for multilevel surgeries, the consensus of the current panel is that surgery 
on the foot to improve the varus positioning and on the Achilles tendon to improve 
dorsiflexion range might be sufficient to improve gait in patients with clinically significant 
ankle contracture and good quadriceps and hip extensor strength. Interventions related to the 
hips and knees are not recommended.
Assessment for scoliosis should be done at least annually, although onset is unusual in the 
ambulatory stage. Visual assessment is appropriate, with radiographic assessment only if a 
curve is observed on examination or if visual inspection alone is inadequate, such as in 
children with obesity. The preceding section on bone health and osteoporosis management 
provides information regarding monitoring and treatment of spinal compression fractures. 
Use of spinal orthoses is not generally recommended in the setting of a compression 
fracture.
Anticipatory guidance during routine clinic visits is an important part of a fracture 
prevention programme throughout all disease stages (figure 5). As noted, corticosteroids 
have been associated with osteoporosis and subsequent vertebral fractures in DMD.100 In a 
study of 143 boys with DMD, the long-bone fracture rate in those treated with 
corticosteroids was 2·6 times greater than in those who had never received steroids.68 A 
lower-limb fracture during the ambulatory stage might need aggressive management to 
maintain ambulation. Internal or external fixation allows for early mobilisation compared 
with casting or splinting.101
There have been case reports of fat embolism syndrome in boys with DMD and acute 
fracture or trauma to the lower extremities.74,75 Boys with fat embolism syndrome present 
with altered mental status, respiratory distress, and tachycardia, which should prompt 
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immediate medical attention due to high morbidity and mortality associated with this 
condition. Current treatment focuses on supportive respiratory care and high-dose 
corticosteroids.102
Early non-ambulatory stage
Foot and ankle surgery to improve equinovarus foot might help with foot positioning in the 
wheelchair or for shoe wear, but is typically done only if a patient requests the procedure. 
After foot and ankle surgery, use of ankle-foot orthoses will be needed during the daytime to 
prevent a recurrence of the contractures.
Inspection of the spine should be part of every clinical examination. Experienced clinicians 
should be able to monitor the spine in non-ambulatory boys by visual inspection alone; 
however, less experienced clinicians should obtain a spine radiograph when a child first 
becomes non-ambulatory. A spine radiograph is also useful when inspection is unhelpful, 
such as in children with obesity. Once a curve has been detected with radiography, further 
surveillance depends on the skeletal maturity of the individual; skeletally immature 
individuals should undergo radiographs once every 6 months, and skeletally mature 
individuals should undergo radiographs at least once a year. A curve of 20° or more should 
warrant involvement of an orthopaedic surgeon. The use of spinal orthoses is not 
recommended. In contrast to the typical clinical course in untreated boys, patients treated 
with corticosteroids have milder spinal curvatures and less frequent need for spinal 
surgeries.68,71,100,103
Despite an absence of RCTs, we advise posterior spinal fusion in young men with DMD, 
given the positive effect on function, sitting balance and tolerance, pain, and quality of life 
observed in non-randomised, prospective cohort studies.28,104,105 Posterior spinal 
instrumentation and fusion are recommended in non-ambulatory individuals who have a 
spinal curve in the sitting position greater than 20-30°, who have not yet reached puberty, 
and who have not been treated with corticosteroids because the curve is expected to 
progress. Although patients treated with corticosteroids can still develop scoliosis, the 
progression might be less predictable, so observation for clear evidence of progression is a 
reasonable approach before intervening. An anterior spinal fusion approach is not required 
as the fusion is generally done in the second decade when little additional longitudinal spine 
growth is anticipated.
When surgical correction for scoliosis is done, stabilisation into the pelvis and fusion are 
advised in those with a pelvic obliquity of greater than 15° to assist with seating and 
positioning. In those without a severe pelvic obliquity, fusion to the lower lumbar vertebra is 
sufficient. The goal of surgical intervention for the spine is to prevent further progression of 
scoliosis, improve sitting tolerance, and reduce pain.28
Anticipatory fracture prevention guidance should continue through the non-ambulatory 
stages (figure 5). A more conservative approach to management of lower-limb fractures is 
advised in non-ambulatory children because the goal is no longer to bear weight. Internal 
fixation might be necessary for an unstable fracture, but splinting might be sufficient for 
bone healing and pain control. Pain management is important for all children, but special 
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monitoring could be necessary in the setting of pulmonary and cardiac compromise. Health-
care providers and families should be aware of fat embolism syndrome, as described above.
Late non-ambulatory stage
Surgical interventions to manage contractures involving the upper or lower extremities are 
not recommended during the late non-ambulatory stage of DMD unless pain, positioning, or 
skin integrity is the concern.
Clinicians should examine the spine at every clinical visit. Individuals with known scoliosis 
should have yearly anteroposterior upright spinal radiographs when there is any concern 
about progression. Posterior spinal fusion is recommended during the late non-ambulatory 
stage for those with a progressive curve. It is essential to consult with the patient’s 
respiratory physician and cardiologist to ensure that lung and heart function are sufficient to 
proceed with this surgical intervention. Some studies indicate that spinal fusion slows the 
progression of respiratory decline, whereas others show no significant difference in the rate 
of decline postoperatively.28,106-108
The treatment of an acute fracture during the late non-ambulatory stage is similar to that in 
the early non-ambulatory stage, with the goals of fracture stabilisation and pain control. Cast 
or splint management is usually sufficient in the setting of a distal femoral metaphyseal 
fracture. In the case of a proximal femur fracture, operative stabilisation is necessary. As 
with any fracture, providers and families should be aware of fat embolism syndrome.
Surgical considerations
Important surgical considerations for individuals with DMD are detailed in figure 6. Young 
men with DMD are at risk of potentially fatal rhabdomyolysis and hyperkalaemia when 
exposed to inhalational anaesthetics or when given suxamethonium chloride 
(succinylcholine).109 A cardiologist and respiratory physician should be consulted before all 
surgical procedures, and anaesthetists should be aware that individuals with DMD are at risk 
of cardiac and respiratory decompensation during and after surgery.110 A detailed discussion 
of surgical considerations is provided in the appendix.
Conclusions and future directions
Improved approaches to respiratory, cardiac, bone health and osteoporosis, and orthopaedic 
and surgical management can now be offered to children and adults with DMD. However, 
despite advances in our knowledge and understanding of best approaches to management, 
progress is needed across these subspecialties to meet the needs of patients.
For respiratory management, diagnostic tools and measures that might have clinical 
relevance but need further study include assisted cough peak flow, maximum insufflation 
capacity, the difference between maximum insufflation capacity and FVC, supine FVC, 
highest flow generated during an inspiratory FVC manoeuvre, the rapid shallow breathing 
index, and sniff nasal inspiratory pressure. Therapies for which research is needed to 
establish efficacy and optimum use include high-frequency chest oscillation, intrapulmonary 
percussive ventilation, and negative-pressure ventilation. Improved understanding of 
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pulmonary phenotypic variability and of the effect of cardiac function and nutritional status 
on the respiratory system is needed to optimise care and to develop pulmonary outcome 
measures to assess the efficacy of current and emerging DMD therapies. Prospective studies 
are needed to assess the criteria recommended in this document for initiation of cough 
assistance and non-invasive ventilation, with use of clinically relevant outcome measures to 
develop evidence-based guidelines.
Cardiac outcomes should be included in clinical trials because survival will not improve if 
emerging therapies do not effectively treat DMD cardiomyopathy. Biomarkers that indicate 
short-term attenuation of disease-related progression need to be identified. Novel 
dystrophin-specific cardiac treatments are needed to improve patient outcomes. The natural 
history of cardiomyopathy in female carriers of a disease-causing mutation needs to be 
clarified, and studies are needed to identify the best diagnostic and therapeutic strategies for 
affected girls and women.
Because vertebral fractures are an early manifestation of bone fragility and the adverse 
effects of glucocorticoids occur rapidly, longitudinal trials addressing osteoporosis 
prevention should originate with young patients, with vertebral fractures as a key outcome 
measure. Further studies are also needed to assess the potential of growth-promoting 
therapies to prevent bone fragility and of anabolic agents, such as parathyroid hormone or 
antisclerostin antibody, to treat osteoporosis.
Controlled trials of surgical techniques for orthopaedic management, when appropriate, are 
needed, as is a better understanding of musculoskeletal complications and of the best 
outcome measures to assess musculoskeletal effects of available and emerging DMD 
therapies. More studies of patient-reported and family-reported outcomes would help to 
guide decision making about lower-extremity surgeries and spinal fusion.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Assessments and interventions for respiratory care of patients with Duchenne muscular 
dystrophy by stage of disease
DMD=Duchenne muscular dystrophy. FVC=forced vital capacity. MEP=maximum 
expiratory pressure. MIP=maximum inspiratory pressure. PCF=peak cough flow. 
petCO2=end-tidal partial pressure of CO2. ptcCO2=transcutaneous partial pressure of CO2. 
SpO2=blood oxygen saturation by pulse oximetry. *See text for definitions of sleep study 
results. †All specified threshold values of PCF, MEP, and MIP apply to older teenage and 
adult patients. ‡Fatigue, dyspnoea, morning or continuous headaches, frequent nocturnal 
awakenings or difficult arousal, hypersomnolence, difficulty concentrating, awakenings with 
dyspnoea and tachycardia, or frequent nightmares. §We strongly endorse the use of non-
invasive methods of assisted ventilation instead of tracheostomy to optimise patient quality 
of life; indications for tracheostomy include patient preference, inability of patient to use 
non-invasive ventilation successfully, three failed extubation attempts during a critical illness 
despite optimum use of non-invasive ventilation and mechanically assisted coughing, or 
failure of non-invasive methods of cough assistance to prevent aspiration of secretions into 
the lungs due to weak bulbar muscles.
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Figure 2. 
Cardiac monitoring, diagnosis, and treatment algorithm for patients with Duchenne 
muscular dystrophy
Birnkrant et al. Page 24
Lancet Neurol. Author manuscript; available in PMC 2018 April 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Osteoporosis monitoring, diagnosis, and treatment algorithm for patients with 
Duchenne muscular dystrophy
BMD=bone mineral density. DMD=Duchenne muscular dystrophy. DXA=dual-energy x-ray 
absorptiometry. *Signs of clinically significant bone fragility are low-trauma fractures of 
long bones or vertebra. †Clinical stability refers to absence of non-vertebral fractures, stable 
healed vertebral fractures, absence of new vertebral fractures in previously normal vertebral 
bodies, absence of bone and back pain, and BMD Z score appropriate for height Z score or 
higher than −2 SD.
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Figure 4. 
Considerations for orthopaedic and surgical care of patients with Duchenne muscular 
dystrophy by stage of disease
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Figure 5. 
General guidance on fracture prevention for patients with Duchenne muscular dystrophy and 
their families
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Figure 6. Surgical considerations for patients with Duchenne muscular dystrophy
DMD=Duchenne muscular dystrophy. FVC=forced vital capacity. *Guidance applies to 
older teenage and adult patients.
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